Effects of RG1068 (Secretin) on Information Processing in Schizophrenia
Schizophrenia
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring Schizophrenia, Secretin
Eligibility Criteria
Inclusion Criteria: Able to give informed consent DSM-IV diagnosis of schizophrenia 18-55 years of age Stable medication > 4 weeks Exclusion Criteria: Active suicidal ideation Concurrent DSM-IV comorbidity with any substance dependence A urine drug screen that is qualitatively positive for controlled substances Abnormal hepatic function (AST or ALT > 2.5 X the upper limit of normal, or bilirubin > 1.5 X the upper limit of normal) Abnormal renal function (BUN or creatinine > 1.5 X the upper limit of normal) Abnormal bone marrow function (WBC < 4 x 103/mm3, Platelets <100 x 103/mm3 and hemoglobin <10 g/dl) Any history of sensitivity to any of the ingredients in the study drug Clinically significant organic disease including cardiovascular, hepatic, pulmonary, neurologic, or renal disease or other medical condition, serious intercurrent illness, or extenuating circumstances that, in the opinion of the Investigator, would interfere with the performance or interpretability of, or put the patient at risk from, the study procedures. Women who are pregnant, breastfeeding, or refuse to use adequate birth control
Sites / Locations
- LaRue Carter Hospital